§ Federal grant opportunity · PAR-27-065
NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
National Institutes of Health is accepting applications for NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required). The deadline is March 9, 2029 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- March 9, 2029
- Award range
- Award amount not published
- Eligibility
- state governments, public and indian housing authorities, for profit organizations other than small businesses, other native american tribal organizations, other, nonprofits non higher education with 501c3, federally recognized native american tribal governments, private institutions of higher education, county governments, nonprofits non higher education without 501c3, public and state institutions of higher education, city or township governments, special district governments, small businesses, independent school districts
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PAR-27-065
Program overview
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS and may include studies of small molecules, biologics, devices as well as surgical, behavioral, diet-based, or rehabilitation therapies. Studies addressing neurological diseases and care across the lifespan are highly encouraged. This notice invites both early- and middle-phase exploratory clinical trials as well as later phase confirmatory Phase 3 or comparative effectiveness clinical trials.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before March 9, 2029, allowing time for registration and validation.
Related grant opportunities
- Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Not Allowed)
- Mathematical Sciences Research Institutes
- Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)
- ARMY APPLICATIONS LAB BROAD AGENCY ANNOUNCEMENT FOR DISRUPTIVE APPLICATIONS
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.